# Essentia BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/essentia-biosciences

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.essentiabiosciences.com
- Latest round: Angel (Oct 24, 2023)
- Investors on record: 5

## About

Established in 2021 and based in Beijing, China, Beijing Yisheng Biotechnology Co., Ltd, trading as Essentia BioSciences is a biotechnology company specializing in the development, manufacture and marketing of human induced pluripotent stem cell-derived cellular drugs and generic iPSC (induced pluripotent stem cells) drugs. The core team consists of people from Cambridge University, Oxford University and Peking University. It was awarded the title of Zhongguancun High-Tech Enterprise in March 2023. In January 2026, Essentia BioSciences raised approximately CNY 100 million in Pre-Series A funding co-led by new investors Haier Capital and Foxconn Technology Group, with participation from returning investor YuanBio Venture, Beijing Molecular Technology and new investors Zero2IPO Ventures, He Ding Gong Capital.
The company is engaged in the research, development, manufacture and sale of human induced pluripotent stem cell-derived cell drugs and generic iPSC drugs. It also provides treatment options for serious illnesses such as diabetes, cardiovascular disease, and neurodegenerative diseases.
The company generates revenue by developing human induced pluripotent stem cell-derived cellular drugs and generic iPSC (induced pluripotent stem cells) drugs.

## Funding rounds

- Angel, Oct 24, 2023 — Peiyang Begonia, Beijing Yiyuan Investment Management, Beijing New Aerotropolis Fund Management, Beijing Molecular Technology
- Angel, Mar 30, 2022 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Peiyang Begonia — Angel
- Beijing Yiyuan Investment Management — Angel
- Beijing New Aerotropolis Fund Management (https://capitalatlas.ai/funds/beijing-new-aerotropolis-fund-management) — Angel
- Beijing Molecular Technology — Angel